Circumferential Pulmonary Vein Isolation Alone Versus CPVI Plus Low-Voltage Areas Ablation During SR Versus CPVI Plus Low-Voltage Areas Ablation During AF for the Treatment of CAF

Yantai Yuhuangding Hospital0 sites150 target enrollmentJuly 15, 2024

ConditionsAtrial Fibrillation

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Atrial Fibrillation
Sponsor: Yantai Yuhuangding Hospital
Enrollment: 150
Primary Endpoint: The incidence of no atrial arrhythmias greater than 30 seconds
Status: Not yet recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The primary objective of this investigation is to compare the efficacy of Three different AF ablation strategies in patients with Persistent atrial fibrillation: CPVI plus Low-Voltage Areas ablation during sinus rhythm Versus. CPVI Plus Low-Voltage Areas Ablation During AF and CPVI alone.

Registry

clinicaltrials.gov

Start Date

July 15, 2024

End Date

December 15, 2026

Last Updated

last year

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Yantai Yuhuangding Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients age is 18-80 years;
•Patients with non-paroxysmal AF; non-paroxysmal AF will be defined as a sustained episode lasting \> 7 days;
•Patients can sign the written informed consent for the study;
•Patients can endure the required follow-up.

Exclusion Criteria

•Patients who had previously undergone atrial fibrillation, atrial tachycardia, or atypical atrial flutter ablation
•Preoperative combined atrial tachycardia (≥30S) and atypical atrial flutter
•Left atrial diameter \>55mm
•Left ventricular ejection fraction \<35%
•Left atrial thrombus
•Postoperative cardiac surgery
•After valve replacement
•After permanent pacemaker implantation
•hypertrophic cardiomyopathy
•Patients with moderate-to-severe aortic valve disease, moderate-to-severe mitral stenosis, and severe other valvular disease

Outcomes

Primary Outcomes

The incidence of no atrial arrhythmias greater than 30 seconds

Time Frame: at least 18 months follow up

The incidence of no atrial arrhythmias greater than 30 seconds

Secondary Outcomes

No use of antiarrhythmic drugs and no occurrence of atrial tachycardia/flutter exceeding 30 seconds(at least 18 months follow up)
Atrial fibrillation load(at least 18 months follow up)
No use of antiarrhythmic drugs and no occurrence of atrial fibrillation exceeding 30 seconds(at least 18 months follow up)
Procedure time(Surgical procedure)
Ablation time(1 week after patient enrollment)
Incidence of peri-procedural complications(at least 18 months follow up)